Program
carfilzomib
Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Waldenstrom Macroglobulinemia · Hematologic Neoplasms, led by 5 companies.
Drug pageCarfilzomib: every studyMany companies study it; this page follows only the 33 they lead. All 157 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 230 open or running | phase 4since Apr 16, 2019 | Sep 6, 2005 | none ahead |
| AbbVieits history only | 32 open or running | phase 3since Nov 28, 2023 | Sep 27, 2013 | Jun 2027phase 2 · NCT02899052 |
| Criteriumits history only | 30 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Oncotherapeuticsits history only | 20 open or running | phase 2since Jan 3, 2013 | Jan 3, 2013 | none ahead |
| Sanofiits history only | 22 open or running | phase 2since Jan 20, 2023 | Jan 20, 2023 | Apr 1, 2027phase 2 · NCT06356571 |
Also a collaborator on its studies: Bristol-Myers Squibb and Onyx Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Sep 6, 2005.
- Nov 6, 2013Phase 2 study in Small Cell Lung CarcinomaAmgen · NCT01987232 · 32 enrolled · United States, Canada, Russian Federation
- Dec 23, 2014Phase 1 study in Multiple MyelomaAmgen · NCT02335983 · 107 enrolled · United States
- Apr 6, 2015Phase 3 study in Multiple MyelomaAmgen · NCT02412878 · 478 enrolled · United States, Australia, Belgium and more
- Sep 1, 2016Phase 2 study in Multiple MyelomaAbbVie · NCT02899052 · 120 enrolled · United States, Australia, Hungary and more
- Nov 11, 2016Phase 3 study in RecurrenceAmgen · NCT03029234 · 126 enrolled · China
- Feb 27, 2017Phase 2 study in Multiple MyelomaOncotherapeutics · NCT03104270 · 13 enrolled · United States
- Apr 2, 2018Phase 2 study in RecurrenceAmgen · NCT03512353 · 7 enrolled · United States
- Jan 14, 2019Phase 3 study in RecurrenceAmgen · NCT03859427 · 454 enrolled · United States, Austria, Bulgaria and more
- Apr 16, 2019Phase 4 study in Multiple MyelomaAmgen · NCT03934684 · 101 enrolled · India
- Nov 22, 2019Phase 2 study in RecurrenceAmgen · NCT04191616 · 54 enrolled · United States, Denmark, Estonia and more
- Jan 20, 2023Sanofi’s first study: phase 2 study in Multiple MyelomaNew to SanofiSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
- Nov 28, 2023Phase 3 study in Multiple MyelomaAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
- Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571 · 64 enrolled · United States
- Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571
- Jun 2027Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT02899052
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaAbbVie · NCT06158841
TargetBeta
“26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bortezomibrule | Johnson & Johnson | phase 4 | 85 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06356571Plasma Cell Myeloma Refractory · United States | 2 | Active, not recruiting | Sanofi | Apr 1, 2027 | 64 |
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Dec 2027 | 421 |
| NCT05704049Multiple Myeloma · Australia, Brazil, China and more | 2 | Active, not recruiting | Sanofi | Dec 22, 2025 | 118 |
| NCT04191616Recurrence · United States, Denmark, Estonia and more | 2 | Completed | Amgen | Nov 30, 2022 | 54 |
| NCT03934684Multiple Myeloma · India | 4 | Completed | Amgen | Mar 23, 2023 | 101 |
| NCT03859427Recurrence · United States, Austria, Bulgaria and more | 3 | Completed | Amgen | Mar 31, 2023 | 454 |
| NCT03512353Recurrence · United States | 2 | Terminated | Amgen | Jan 16, 2020 | 7 |
| NCT03104270Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 25, 2019 | 13 |
| NCT03029234Recurrence · China | 3 | Completed | Amgen | Nov 5, 2018 | 126 |
| NCT02899052Multiple Myeloma · United States, Australia, Hungary and more | 2 | Active, not recruiting | AbbVie | Jun 2027 | 120 |
| NCT02412878Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Amgen | Jun 15, 2017 | 478 |
| NCT02335983Multiple Myeloma · United States | 1 | Completed | Amgen | Oct 28, 2019 | 107 |
| NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation | 2 | Completed | Amgen | Aug 2016 | 32 |
| NCT01980589Multiple Myeloma · United States | 1 | Completed | Amgen | Mar 2016 | 22 |
| NCT01962792Multiple Myeloma · United States, Canada | 2 | Completed | AbbVie | Mar 2019 | 84 |
| NCT01949545Hematologic Neoplasms · United States, France, Netherlands and more | 1 | Completed | Amgen | Aug 2015 | 46 |
| NCT01949532Multiple Myeloma · United States, Australia, Canada | 1 | Completed | Amgen | Apr 2015 | 26 |
| NCT01818752Multiple Myeloma · United States, Argentina, Australia and more | 3 | Completed | Amgen | Jul 15, 2016 | 955 |
| NCT01789242Amyloidosis · United States | 1 | Completed | Criterium | Dec 2016 | 32 |
| NCT01792102Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Dec 2018 | 38 |
| NCT01677858Multiple Myeloma · United States | 2 | Completed | Amgen | Jul 22, 2016 | 116 |
| NCT01660750Multiple Myeloma · United States | 1 | Completed | Criterium | Aug 2015 | 29 |
| NCT01568866Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Amgen | Nov 10, 2014 | 929 |
| NCT01464034Multiple Myeloma · United States | 2 | Terminated | Criterium | Jul 2020 | 136 |
| NCT01302392Multiple Myeloma · Australia, Austria, Belgium and more | 3 | Completed | Amgen | Jul 2014 | 315 |
| NCT01080391Multiple Myeloma · United States, Austria, Belgium and more | 3 | Completed | Amgen | Jun 16, 2014 | 792 |
| NCT00884312Multiple Myeloma · United States, Canada | 2 | Completed | Amgen | May 17, 2017 | 101 |
| NCT00721734Multiple Myeloma · United States | 2 | Completed | Amgen | Nov 2012 | 50 |
| NCT00603447Multiple Myeloma · United States, Canada | 1 | Completed | Amgen | May 2013 | 84 |
| NCT00531284Ovarian Neoplasms · United States | 2 | Completed | Amgen | Oct 2014 | 184 |
| NCT00530816Multiple Myeloma · United States, Canada | 2 | Completed | Amgen | Jan 2013 | 164 |
| NCT00511238Multiple Myeloma · United States, Canada | 2 | Completed | Amgen | Nov 2010 | 312 |
| NCT00150462Waldenstrom Macroglobulinemia · United States | 1 | Completed | Amgen | Oct 2009 | 48 |
How it is read
Names in the registry
- “Carfilzomib”, 34 entries
- “carfilzomib”, 3 entries
- “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
- “Drug: Carfilzomib + Dexamethasone”, 1 entry
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 33 studies
- Amyloidosis, 1 study
- Small Cell Lung Carcinoma, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.